Vandetanib in Advanced Medullary Thyroid Cancer: Review of Adverse Event Management Strategies

Author： Grande Enrique   Kreissl Michael   Filetti Sebastiano   Newbold Kate   Reinisch Walter   Robert Caroline   Schlumberger Martin   Tolstrup Lærke   Zamorano Jose   Capdevila Jaume  

Publisher： Springer Publishing Company

ISSN： 0741-238X

Source： Advances in Therapy, Vol.30, Iss.11, 2013-11, pp. : 945-966

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Vandetanib for aggressive and symptomatic medullary thyroid cancer

By Deshpande Hari A   Carling Tobias   Khan Nabeela   Holt Elizabeth  

Clinical Practice, Vol. 10, Iss. 3, 2013-05 ,pp. : 275-282

Future Medicine

Access to resources Recommend Favorite

Vandetanib‐associated alopecia areata in a patient with metastatic medullary thyroid cancer

By  

INTERNATIONAL JOURNAL OF DERMATOLOGY, Vol. 54, Iss. 6, 2015-06 ,pp. : e213-e216

John Wiley & Sons Inc

Access to resources Recommend Favorite

Medical management of metastatic medullary thyroid cancer

By  

CANCER, Vol. 120, Iss. 21, 2014-11 ,pp. : 3287-3301

John Wiley & Sons Inc

Access to resources Recommend Favorite

Surgical Approach to the Management of Medullary Thyroid Cancer: When Is Lymph Node Dissection Needed?

By  

Oncology, Vol. 84, Iss. 6, 2013-05 ,pp. : 350-355

Karger

Access to resources Recommend Favorite

Twenty years of lesson learning: how does the RET genetic screening test impact the clinical management of medullary thyroid cancer?

By  

CLINICAL ENDOCRINOLOGY, Vol. 82, Iss. 6, 2015-06 ,pp. : 892-899

John Wiley & Sons Inc

Access to resources Recommend Favorite